Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen

Journal of Nuclear Medicine

Volumn 56, Issue 9, 2015, Pages 1401-1407

  Kiess, Ana P ^a   Minn, Il ^b   Chen, Ying ^b   Hobbs, Robert ^a   Sgouros, George ^a,b   Mease, Ronnie C ^b   Pullambhatla, Mrudula ^b   Shen, Colette J ^a   Foss, Catherine A ^b   Pomper, Martin G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Auger; Iodine; Prostate cancer; PSMA; Radiopharmaceutical therapy; Radiotherapy

Indexed keywords

2 [3 [1 CARBOXY 5 (4 IODOBENZOYLAMINO)PENTYL]UREIDO]PENTANEDIOIC ACID I 125; DNA; FLUORESCENT DYE; HISTONE H2A; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; SODIUM IODIDE I 125; UNCLASSIFIED DRUG; YC 36; 2-(3-(1-CARBOXY-5-((6-FLUOROPYRIDINE-3-CARBONYL)AMINO)PENTYL)UREIDO)PENTANEDIOIC ACID; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; LYSINE; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUGER ELECTRON SPECTROSCOPY; CANCER INHIBITION; CANCER SIZE; CELL MEMBRANE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROMETASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TREATMENT DURATION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; APOPTOSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE; TREATMENT OUTCOME; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IODINE RADIOISOTOPES; KALLIKREINS; LYSINE; MALE; MOLECULAR TARGETED THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RADIOTHERAPY; TREATMENT OUTCOME; UREA;

EID: 84941009295     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.155929     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Previous Version: SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Surveillance, epidemiology and end results program website. http://seer.cancer.gov/csr/1975-2009-pops09. Updated August 20, 2012. Accessed July 14, 2015.
3. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32-39.
4. Caire AA, Sun L, Ode O, et al. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology. 2009;74:643-647.
5. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-222 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
6. Kassis AI. The amazing world of auger electrons. Int J Radiat Biol. 2004;80: 789-803.
7. Bodei L, Kassis AI, Adelstein SJ, Mariani G. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications. Cancer Biother Radiopharm. 2003;18:861-877.
8. Chen Y, Foss CA, Byun Y, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008;51:7933-7943.
9. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
10. Chang SS, Heston WD. The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol. 2002;7:7-12.
11. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 highaffinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380-387.
12. Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostatespecific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-1891.
13. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium- 99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517.
14. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines - part 2. J Urol. 2005;173:360-372.
15. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines - part 1. J Urol. 2005;173:342-359.
16. Novy Z, Barta P, Mandikova J, Laznicek M, Trejtnar F. A comparison of in vitro methods for determining the membrane receptor expression in cell lines. Nucl Med Biol. 2012;39:893-896.
17. Wang X, Ma D, Olson WC, Heston WD. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther. 2011;10:1728-1739.
18. Govindan SV, Goldenberg DM, Elsamra SE, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. J Nucl Med. 2000;41: 2089-2097.
19. Chen Y, Pullambhatla M, Banerjee SR, et al. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem. 2012;23:2377-2385.
20. Chen Y, Dhara S, Banerjee SR, et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun. 2009;390: 624-629.
21. Roch-Lefèvre S, Mandina T, Voisin P, et al. Quantification of gamma-H2AX foci in human lymphocytes: a method for biological dosimetry after ionizing radiation exposure. Radiat Res. 2010;174:185-194.
22. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315-2319.
23. Agostinelli S, Allison J, Amako K, et al. GEANT4-α simulation toolkit. Nucl Instrum Meth A. 2003;506:250-303.
24. Humm JL, Howell RW, Rao DV. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys. 1994;21:1901-1915.
25. Kassis AI. Cancer therapy with Auger electrons: are we almost there? J Nucl Med. 2003;44:1479-1481.
26. Kassis AI. Molecular and cellular radiobiological effects of Auger emitting radionuclides. Radiat Prot Dosimetry. 2011;143:241-247.
27. Sastry KS. Biological effects of the Auger emitter iodine-125: a review. Report No. 1 of AAPM Nuclear Medicine Task Group No. 6. Med Phys. 1992;19:1361-1370.
28. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res. 2003;63: 2645-2648.
29. Rajasekaran SA, Christiansen JJ, Schmid I, et al. Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther. 2008;7:2142-2151.
30. Balagurumoorthy P, Xu X, Wang K, Adelstein SJ, Kassis AI. Effect of distance between decaying 125I and DNA on Auger-electron induced double-strand break yield. Int J Radiat Biol. 2012;88:998-1008.
31. Pouget JP, Santoro L, Raymond L, et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res. 2008;170:192-200.
32. Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM. Trastuzumabresistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med. 2008;49:1498-1505.
33. Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. Clin Cancer Res. 2005;11:777-786.
34. Barinka C, Byun Y, Dusich CL, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008;51:7737-7743.
35. Hillier S, Rubino K, Maresca K, et al. [131I]MIP-1466, a small molecule prostatespecific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer [abstract]. J Nucl Med. 2012;53(suppl 1):170.
36. Tagawa ST, Beltran H, Vallabhajosula S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010;116(4, suppl): 1075-1083.
37. Hobbs RF, Song H, Huso DL, Sundel MH, Sgouros G. A nephron-based model of the kidneys for macro-to-micro alpha-particle dosimetry. Phys Med Biol. 2012;57:4403-4424.